Activity and safety of dose-adjusted infusional cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy with rituximab in very elderly patients with poor-prognostic untreated diffuse large B-cell non-Hodgkin lymphoma

Cancer

Volumn 117, Issue 5, 2011, Pages 964-973

  Musolino, Antonino ^a   Boggiani, Daniela ^a   Panebianco, Michele ^a   Vasini, Giovanna ^a   Salvagni, Stefania ^a   Franciosi, Vittorio ^a   Ardizzoni, Andrea ^a  

^a UNIVERSITY HOSPITAL OF PARMA   (Italy)

Author keywords

Dose adjusted; Elderly; Infusional CHOP; Non Hodgkin lymphoma; Rituximab

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; RITUXIMAB; VINCRISTINE;

AGED; ANAMNESIS; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CONTINUOUS INFUSION; DIARRHEA; DRUG FATALITY; DRUG SAFETY; EVENT FREE SURVIVAL; FEBRILE NEUTROPENIA; FEMALE; HEART LEFT VENTRICLE FUNCTION; HUMAN; LARGE CELL LYMPHOMA; LIVER TOXICITY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PATIENT SELECTION; PRIORITY JOURNAL; PROGNOSIS; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; NEOADJUVANT THERAPY; PREDNISONE; PROGNOSIS; TREATMENT OUTCOME; VINCRISTINE;

EID: 79952032395     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25582     Document Type: Article

References (47)

1. Muller A, Ihorst G, Mertelsmann R, et al. Epidemiology of non-Hodgkin's lymphoma (NHL): trends, geographic distribution and etiology. Ann Haematol. 2005;84:1-12. (Pubitemid 39625035)
2. Shipp MA, Harrington DP. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med. 1993;329:987-994.
3. The Non-Hodgkin's Lymphoma Classification Project. Effect of age on the characteristics and clinical behavior of non-Hodgkin's lymphoma patients. Ann Oncol. 1997;8:973-978.
4. Burton C, Linch D, Hoskin P, et al. A phase III trial comparing CHOP to PMitCEBO with or without G-CSF in patients aged 60 plus with aggressive non-Hodgkin's lymphoma. Br J Cancer. 2006;94:806-813.
5. Vose JM, Armitage JO, Weisenburger DD, et al. The importance of age in survival of patients treated with chemotherapy for aggressive non-Hodgkin's lymphoma. J Clin Oncol. 1988;6:1838-1844. (Pubitemid 19089066)
6. Armitage J, Potter JF. Aggressive chemotherapy for diffuse histiocytic lymphoma in the elderly: increased complications with advancing age. J Am Geriatr Soc. 1984;32:269-273. (Pubitemid 14135573)
7. Wunderlich A, Kloess M, Reiser M, et al. Practicability and acute haematological toxicity of 2- and 3-weekly CHOP and CHOEP chemotherapy for aggressive non-Hodgkin's lymphoma: results from the NHL-B trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Ann Oncol. 2003;14:881-893. (Pubitemid 36827204)
8. Limat S, Demesmay K, Voillat L. Early cardiotoxicity of the CHOP regimen in aggressive non-Hodgkin's lymphoma. Ann Oncol. 2003;14:277-281. (Pubitemid 36305441)
9. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin. Cancer. 2003;97:2869-2879.
10. Lai GM, Chen YN, Mickley LA, et al. P-glycoprotein expression and schedule dependence of adriamicin cytotoxicity in human colon carcinoma cell lines. Int J Cancer. 1991;49:696-703.
11. Legha SS, Benjamin RS, Mackay B. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med. 1982;96:133-139. (Pubitemid 12172323)
12. Gutierrez M, Chabner BA, Pearson D, et al. Role of a doxorubicin- containing regimen in relapsed and resistant lymphomas: an 8-year follow-up study of EPOCH. J Clin Oncol. 2000;18:3633-3642.
13. Wilson WH, Bates SE, Fojo A, et al. Controlled trial of dexverapamil, a modulator of multidrug resistance, in lymphoma refractory to EPOCH chemotherapy. J Clin Oncol. 1995;13:1995-2004.
14. Ackland SP, Ratain MJ, Vogelzang NJ, Choi KE, Ruane M, Sinkule JA Pharmacokinetics and pharmacodynamics of longterm continuous-infusion doxorubicin. Clin Pharmacol Ther. 1989;45:340-347.
15. Wilson WH, Dunleavy K, Pittaluga S, et al. Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy. Blood. 2002;99:2685-2693. (Pubitemid 34525353)
16. Garcia-Suarez J, Banas H, Arribas I, et al. Dose-adjusted EPOCH plus rituximab is an effective regimen in patients with poor-prognostic untreated diffuse large B-cell lymphoma: results from a prospective observational study. Br J Haematol. 2006;136:276-285.
17. Wilson WH, Dunleavy K, Pittaluga S, et al. Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers. J Clin Oncol. 2008;16:2717-2724.
18. Little RF, Pittaluga S, Grant N, et al. Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology. Blood. 2003;101:4653-4659. (Pubitemid 36857717)
19. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N Engl J Med. 2002;346:235-242. (Pubitemid 34438862)
20. Jaffe ES. The 2008 WHO classification of lymphomas: implications for clinical practice and translational research. Hematology Am Soc Hematol Educ Program. 2009:523-531.
21. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999;17:1244-1253. (Pubitemid 29162950)
22. Hryniuk W, Bush H. The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol. 1984;2:1281-1288. (Pubitemid 15202705)
23. National Cancer Institute. CTCAE v3.0 Available at: http://ctep.cancer. gov Accessed June 24, 2010.
24. Gehan EA. The determination of the number of patients required in a preliminary and follow-up trial of a new chemotherapy agent. J Chronic Dis. 1961;13:346-353.
25. Kaplan EL, Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
26. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966;50:163-170.
27. Cox DR. Regression models and life tables. J R Stat Soc. 1972;34:187-220.
28. Freeman DH. Applied Categorical Data Analysis. New York: Marcel Dekker; 1987.
29. Hilbe JM. Logistic Regression Models. Virginia Beach, VA: Chapman & Hall/CRC Press; 2009.
30. Habermann TM, Weller EA, Morrison VA, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol. 2006;24:3121-3127. (Pubitemid 46638950)
31. Ishii K, Urase F, Nagare Y, et al. VNCOP-B plus rituximab therapy in elderly patients with aggressive B-cell non-Hodgkin lymphoma: a multicenter experience. Arch Gerontol Geriatr. 2010;51:209-215.
32. Italiano A, Jardin F, Peyrade F, et al. Adapted CHOP plus rituximab in non-Hodgkin's lymphoma in patients over 80 years old. Haematologica. 2005;90:1281-1283. (Pubitemid 41375292)
33. Zinzani PL, Storti S, Zaccaria A, et al. Elderly aggressive-histology Non-Hodkin's Lymphoma: first-line VNCOP-B regimen experience on 350 patients. Blood. 1999;94:33-38. (Pubitemid 29300131)
34. O'Connel MJ, Earle JD, Harrington DP, et al. Initial chemotherapy doses for elderly patients with malignant lymphoma. J Clin Oncol. 1986;4:1418.
35. Sonneveld P, Michiels JJ. Full-dose chemotherapy in elderly patients with non-Hodgkin's lymphoma. A feasibility study using a mitoxantrone-containing regimen. Br J Cancer. 1990;62:105-108. (Pubitemid 20226455)
36. Tirelli U, Zagonel V, Errante D, et al. A prospective study of a new combination chemotherapy regimen in patients older than 70 years with unfavourable non-Hodgkin's lymphoma. J Clin Oncol. 1992;10:228-236.
37. Salvagno L, Contu A, Bianco A. A combination of mitoxantrone, etoposide and prednisone in elderly patients with non-Hodgkin's lymphoma. Ann Oncol. 1992;3:833-837. (Pubitemid 23002476)
38. O'Reilly SE, Klimo P, Connors JM. Low-dose ACOP-B and VABE. Weekly chemotherapy for elderly patients with advanced-stage diffuse large-cell lymphoma. J Clin Oncol. 1991;9:741-747.
39. Tirelli U, Carbone A, Zagonel V, et al. Non-Hodgkin's lymphoma in the elderly: prospective studies with specifically devised chemotherapy regimens in 66 patients. Eur J Cancer Clin Oncol. 1987;23:535-540. (Pubitemid 17057384)
40. Hainsworth JD, Litchy S, Lamb MR, etal. First-line treatment with brief-duration chemotherapy plus rituximab in elderly patients with intermediate-grade non-Hodgkin's lymphoma: phase II trial. Clin Lymphoma. 2003;4:36-42.
41. Rigacci L, Mappa S, Nassi L, et al. Liposome-encapsulated doxorubicin in combination with cyclophosphamide, vincristine, prednisone and rituximab in patients with lymphoma and concurrent cardiac diseases or pre-treated with anthracyclines. Hematol Oncol. 2001;25:198-203.
42. Visani G, Ferrara F, Alesian F, et al. R-COMP 21 for frail elderly patients with aggressive B-cell non-Hodgkin lymphoma: a pilot study. Leuk Lymphoma. 2008;49:1081-1086. (Pubitemid 351943253)
43. Levine AM, Tulpule A, Espina B, et al. Liposome-encapsulated doxorubicin in combination with standard agents (cyclophosphamide, vincristine, prednisone) in patients with newly diagnosed AIDS-related non-Hodgkin's lymphoma: results of therapy and correlates of response. J Clin Oncol. 2004;22:2662-2670. (Pubitemid 41103754)
44. Luminari S, Montanini A, Caballero D, et al. Nonpegylated liposomal doxorubicin (Myocet™) combination (R-COMP) chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL): results from the phase II EURO18 trial. Ann Oncol. 2010;21:1492-1499.
45. Dixon DO, Neilan B, Jones SE, et al. Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma: the Southwest Oncology Group experience. J Clin Oncol. 1986;4:295-305. (Pubitemid 16133082)
46. Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med. 1993;328:1002-1006. (Pubitemid 23095683)
47. Hoerni B, Sotto JJ, Eghbali H, et al. Non-Hodgkin's malignant lymphomas in patients older than 80. Cancer. 1988;61:2057-2059.